This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Leo Stolbach, MD; Colin Begg, PhD; John M. Bennett, MD; Murray Silverstein, MD; Geoffrey Falkson, MD; David T. Harris, MD; John Glick, MD

JAMA. 1982;247(3):334-336.

Abstract
To evaluate possible bone marrow toxic reaction related to allopurinol administration, 143 patients with malignant lymphoma were randomized to receive allopurinol for either three or six cycles of chemotherapy. There was no significant difference of nadir WBC or platelet counts. This trial failed to confirm an earlier study that suggested that allopurinol increased the marrow toxic reaction of cytotoxic chemotherapy.

(JAMA 1982;247:334-336)

Author Affiliations
From Tufts University, Boston (Dr Stolbach); the Sidney Farber Cancer Institute, Boston (Dr Begg); the University of Rochester Cancer Center, Rochester, NY (Dr Bennett); the Mayo Clinic, Rochester, Minn (Dr Silverstein); the University of Pretoria, Pretoria, South Africa (Dr Falkson); the American Oncologic Hospital, Philadelphia (Dr Harris); and the Hospital of the University of Pennsylvania, Philadelphia (Dr Glick).

Footnotes
Reprint requests to Ottawa Clinic, The Ontario Cancer Foundation, 190 Melrose Ave, Ottawa, Ontario, Canada K1Y 4K7 (Dr Stolbach).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?